Recently, Efung Capital and several of its invested biopharmaceutical companies have won multiple awards in various authoritative selections, thanks to their exceptional innovation capabilities and industry contributions. Notably, in the TMTPost 2025 H1 Pioneer List, Efung Capital was honored among the Top 20 in the Healthcare Sector. In the Hao Yue Capital Excellence Awards, Core Medical, Norling Bio, and Yingmingda were recognized as Best Innovative Medical Device Companies of the Year, while Coning Bio and Westlake Biosciences were honored as Best Innovative Pharmaceutical Companies of the Year. Additionally, in the list jointly released by PharmaDJ and CMC-CHINA, Ascentage Pharma, Chipscreen Biosciences, Harbour BioMed, Frontier Biotech, Asieris Pharmaceuticals, Cloudbreak Therapeutics, Genuine Biotech, Qyuns Therapeutics, Enbimo Bio, and Xuanzhu Biopharma were honored among the 2025 China Top 101 Innovative Drug Companies.
I. TMTPost 2025 H1 Pioneer List
The TMTPost 2025 H1 Pioneer List is published by "TMTPost VenturePlus," the venture capital-focused media channel under TMTPost. The selection dimensions include the total number of new investments and follow-on investments in existing portfolio companies during H1 2025, the total amount invested, and the number of star projects. The award recognizes pioneer investment institutions that accurately captured industry trends in the new cycle during H1 2025, maintained high-frequency and high-precision investment performance, and consistently pursued and practiced the investment principle of "never missing out."
Efung Capital is recognized among:
Top 20 in the Healthcare Sector
II. The 9th Healthcare Investment Excellence Awards 2025
The 9th Healthcare Investment Excellence Awards 2025 are published by Hao Yue Capital, a leading healthcare industry investment bank in China. The awards comprehensively review metrics such as investment activity, transaction volume, transaction value, and investment returns of healthcare investment funds to select the outstanding investment institutions of the year. Additionally, awards are granted to outstanding healthcare enterprises across various sectors, including innovative pharmaceuticals, innovative medical devices, IVD and life sciences, health services and smart healthcare, and biotechnology. Furthermore, this year's Excellence Awards have expanded the selection scope to include industry parks, virtual data rooms, and other related sectors within the healthcare industry ecosystem.
Several Efung Capital portfolio companies are recognized among:
Best Innovative Pharmaceutical Companies of the Year
Coning Bio
Westlake Biosciences
Best Innovative Medical Device Companies of the Year
Core Medical
Norling Bio
Yingmingda
III. 2025 China Top 101 Innovative Drug Companies & Top 10 Core Industry Chain Lists
The "2025 China Top 101 Pharmaceutical Industry Companies" and the Top 10 Core Industry Chain Lists are authoritative rankings jointly released by PharmaDJ, a pharmaceutical information and precise networking platform, and CMC-CHINA, the China Pharmaceutical Industry Expo. Based on rigorous data analysis and multi-dimensional professional evaluation, this selection aims to recognize benchmark companies and outstanding individuals across various sectors of China's pharmaceutical industry, establish authoritative industry benchmarks, and guide the direction of high-quality industrial development.
Several Efung Capital portfolio companies are recognized among:
2025 China Top 101 Innovative Drug Companies
Ascentage Pharma
Chipscreen Biosciences
Harbour BioMed
Frontier Biotech
Asieris Pharmaceuticals
Cloudbreak Therapeutics
Genuine Biotech
Qyuns Therapeutics
Enbimo Bio
Xuanzhu Biopharma
Looking ahead, Efung Capital will continue to be anchored by its professional investment team, maintain a deep focus on biopharmaceuticals, accelerate the transition of technological achievements from the laboratory to the market, and collectively drive breakthrough developments in China's healthcare and technological innovation sectors.